問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2272Cases

2007-09-01 - 2008-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2007-05-01 - 2008-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated1Sites

Study ended13Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2017-10-01 - 2020-09-30

Phase II/III

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    Unituxin®

Participate Sites
5Sites

Terminated5Sites

劉劍英
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-12-01 - 2016-12-30

Phase III

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

  • Condition/Disease

    Acute Hematogenous Osteomyelitis

  • Test Drug

    daptomycin (CUBICIN)

Participate Sites
5Sites

Terminated5Sites

2015-06-01 - 2017-12-30

Phase II

An Open-Label, Phase II Study to Evaluate SCB01A in Patients with Recurrent or Metastatic Squamous Cell Head and Neck Cancer who have Received Platinum-Based Treatment

  • Condition/Disease

    Squamous Cell Head and Neck Cancer

  • Test Drug

    SCB01A

Participate Sites
6Sites

Terminated6Sites

2014-08-31 - 2016-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2019-10-01 - 2020-12-30

Phase II

A Phase 2a open-label study of the oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect in chronic Hepatitis B (CHB) patients in combination with pegylated interferon alpha2a (peg-IFN) alone and with entecavir (ETV)

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    EYP001a

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2023-06-30 - 2024-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 130 131 132 133 134 228
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB